Wegovy FAERS Safety Signals: What Post-Market Surveillance Data Actually Show

What Is FAERS and Why It Matters for Wegovy

The FDA Adverse Event Reporting System collects voluntary reports of adverse drug experiences from healthcare professionals, patients, and manufacturers after a drug reaches the market. FAERS does not prove causation. It identifies statistical signals that warrant further investigation.

For Wegovy, FAERS data hold particular significance because the drug's approval population (adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity) is far broader and more heterogeneous than clinical trial cohorts. The STEP-1 trial enrolled 1,961 participants under controlled conditions [1]. Real-world prescribing now reaches millions of patients with polypharmacy, rare comorbidities, and off-label use patterns that trials could not capture. FAERS bridges this gap by surfacing adverse events that may have been too rare or too delayed to appear in 68-week studies.

The FDA uses disproportionality analysis (reporting odds ratios and proportional reporting ratios) to compare observed-versus-expected event frequencies. A "signal" means a statistical flag, not a confirmed risk. Between June 2021 and December 2025, semaglutide products generated enough volume for multiple signals to undergo formal evaluation by the FDA's Office of Surveillance and Epidemiology [2].

Gastrointestinal Events: The Dominant Signal Category

GI adverse events account for approximately 40% of all Wegovy-related FAERS submissions. Nausea, vomiting, diarrhea, and constipation are the most frequent individual terms. This aligns precisely with pre-approval data: in STEP-1 to 44.2% of participants on semaglutide 2.4 mg reported nausea versus 17.4% on placebo [1].

The newer and more clinically concerning GI signal involves gastroparesis and delayed gastric emptying. A 2023 analysis published in JAMA identified a statistically significant association between GLP-1 receptor agonist use and gastroparesis diagnoses in a large insurance claims cohort (hazard ratio 3.67; 95% CI 1.15 to 11.90) [3]. The FDA responded by reviewing FAERS gastroparesis reports and issuing updated safety communications. Patients reporting persistent vomiting beyond the dose-escalation phase warrant gastric emptying studies, per the updated Wegovy prescribing information [4].

Intestinal obstruction has also emerged as an active surveillance target. Reports describe ileus-like presentations in patients without prior abdominal surgery. The biological mechanism is plausible: GLP-1 receptor activation slows gut motility globally. The absolute risk remains very low, but the FDA has requested Novo Nordisk provide additional post-marketing data on this outcome.

Pancreatitis: A Persistent Class Concern

Acute pancreatitis has followed the GLP-1 receptor agonist class since exenatide's early post-market years. For semaglutide 2.4 mg specifically, the pooled STEP program incidence was 0.2% versus 0% on placebo. Small numbers, but the FAERS signal persists.

A 2022 systematic review and meta-analysis across all GLP-1 RA trials (N=131,476 patient-years) found no statistically significant increase in pancreatitis (OR 1.03; 95% CI 0.78 to 1.36) [5]. The Endocrine Society's 2024 guideline on obesity pharmacotherapy recommends avoiding GLP-1 RAs in patients with a personal history of pancreatitis but does not contraindicate use in the general population based on current evidence [6].

The Wegovy label carries a Warning and Precaution for acute pancreatitis, instructing prescribers to discontinue if pancreatitis is confirmed and to not restart semaglutide [4]. Lipase elevations without clinical pancreatitis are common (reported in up to 10% of trial participants) and do not independently require drug discontinuation.

Thyroid Neoplasms: The Boxed Warning Signal

Wegovy carries a Boxed Warning for risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning derives entirely from rodent studies in which semaglutide caused dose-dependent thyroid C-cell tumors in both rats and mice at clinically relevant exposures [4].

In humans, the FAERS signal for thyroid neoplasms exists but remains difficult to interpret. A French national health insurance database study (2023, N=2.5 million new antidiabetic drug users) found a modest association between GLP-1 RA use and all thyroid cancer (HR 1.58; 95% CI 1.27 to 1.95) after more than one to three years of cumulative use [7]. The EMA's Pharmacovigilance Risk Assessment Committee reviewed these data and concluded that a causal relationship could not be established given confounding and detection bias [8].

The practical clinical implication: semaglutide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine calcitonin screening in the general Wegovy population is not recommended by the American Thyroid Association [9]. Prescribers should counsel patients to report neck masses, dysphagia, or persistent hoarseness.

Gallbladder Disorders: Cholelithiasis and Cholecystitis

Rapid weight loss is an established risk factor for gallstone formation, independent of drug mechanism. The FAERS signal for cholelithiasis and acute cholecystitis is therefore expected in any effective weight-loss therapy.

In the STEP program, cholelithiasis occurred in 1.6% of semaglutide-treated participants versus 0.7% on placebo. The SELECT cardiovascular outcomes trial (N=17,604) provided larger-scale confirmation: gallbladder-related disorders occurred in 2.8% of the semaglutide group versus 2.3% on placebo [10]. Most cases occurred during the first year of treatment, corresponding to the phase of most rapid weight loss.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center, has noted: "The gallbladder signal is a weight-loss signal, not uniquely a semaglutide signal. We see identical rates with bariatric surgery at comparable weight reductions."

The Wegovy label recommends that prescribers inform patients about gallbladder-related symptoms (right upper quadrant pain, jaundice, fever) and consider ursodiol prophylaxis in patients with prior gallstone history who are losing weight rapidly [4].

Suicidal Ideation: The Emerging Neuropsychiatric Signal

In late 2023, the FDA announced a formal safety evaluation of suicidal ideation and self-injurious behavior associated with GLP-1 receptor agonists following a cluster of FAERS reports and a European Medicines Agency review [11]. This signal generated significant public attention.

The FDA's preliminary findings (published January 2024) analyzed nearly 1,500 FAERS reports mentioning suicidality across all GLP-1 RA products. After adjusting for reporting trends and confounders, the FDA concluded that "available evidence does not establish a causal link between GLP-1 RAs and suicidal thoughts or actions" [11]. The investigation remains open.

The SELECT trial specifically tracked neuropsychiatric adverse events and found no imbalance between semaglutide and placebo groups (suicidal ideation: 0.2% vs. 0.2%) [10]. A retrospective cohort study using TriNetX electronic health records (N=240,618 GLP-1 RA users) found no increased risk of suicidal ideation (adjusted HR 0.73; 95% CI 0.64 to 0.83), suggesting possible protective effects through weight-related quality-of-life improvement [12].

The Wegovy label does not currently include a warning for suicidal ideation. Prescribers should still screen for depression at baseline and during treatment, consistent with standard obesity care.

Cardiovascular Signals: SELECT Changed the Risk Profile

The SELECT trial (N=17,604, median follow-up 39.8 months) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [10]. This finding led to a supplemental FDA approval in March 2024 for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity.

FAERS cardiovascular reports for Wegovy include tachycardia, increased heart rate, and hypotension. Heart rate increases of 1 to 4 beats per minute were documented in the STEP trials and are considered a pharmacologic effect of GLP-1 receptor agonism [1]. The clinical significance of this modest chronotropic effect is addressed by SELECT's favorable MACE outcome. No signal for heart failure exacerbation has emerged.

Aspiration Risk Under Anesthesia

The American Society of Anesthesiologists (ASA) issued a 2023 consensus-based guidance recommending that patients on GLP-1 RAs consider holding doses before elective procedures requiring sedation or general anesthesia [13]. This recommendation stemmed from case reports of aspiration events due to retained gastric contents despite standard fasting protocols.

The FAERS database contains reports of aspiration pneumonitis in Wegovy users undergoing endoscopy or surgery. The ASA recommends holding weekly semaglutide for at least 7 days before elective procedures and considering gastric ultrasound assessment if the drug cannot be held [13]. This guidance applies to all GLP-1 RAs, not Wegovy specifically.

How to Interpret FAERS Limitations

FAERS data have well-documented constraints. Reports are voluntary, so underreporting is the norm (estimated at 1 to 10% of actual events for most drugs). Conversely, media attention creates "stimulated reporting" that inflates signal appearance without reflecting true incidence changes. The 2023 media coverage of GLP-1 RA gastroparesis likely contributed to a reporting spike that does not necessarily indicate increased risk.

Duplicate reports, incomplete data fields, and lack of denominator data (total patients exposed) prevent FAERS from generating true incidence rates. The FDA's Sentinel System, which analyzes electronic health records and claims data from over 100 million patients, provides more rigorous pharmacoepidemiologic evidence and is the FDA's primary tool for confirming or refuting FAERS-generated hypotheses [14].

For clinicians prescribing Wegovy, the appropriate framework is: FAERS signals inform vigilance, not prescribing decisions. The Wegovy label, informed by controlled trial data and validated post-market analyses, remains the authoritative safety reference.

What Prescribers Should Monitor

Based on current FAERS signals and label recommendations, the following monitoring approach is evidence-based for Wegovy patients:

Gastrointestinal: assess symptom burden at each dose escalation. Persistent vomiting beyond week 20 (completion of escalation) warrants evaluation for gastroparesis. Instruct patients to report severe abdominal pain (pancreatitis screen) and right-upper-quadrant symptoms (gallbladder evaluation).

Thyroid: contraindicate in MTC/MEN 2 history. No routine calcitonin screening. Counsel on neck mass symptoms.

Neuropsychiatric: screen PHQ-9 at baseline. Reassess if patients report new mood changes. Document that no causal link is established but monitoring is prudent.

Perioperative: coordinate with anesthesia team. Hold Wegovy at least 7 days before elective procedures requiring sedation. Document GLP-1 RA use in the pre-op medication reconciliation.

Semaglutide 2.4 mg carries a favorable benefit-risk profile supported by the SELECT cardiovascular outcome and STEP weight-loss data, with FAERS surveillance continuing to refine safety understanding in populations underrepresented in trials.